Clinical trials: Atopic Skin
Atopic Dermatitis, Emollients
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients.
- Trial name
- AIMSI (NCT07358000)
- Testing
- Baume Relipid+
- Where
- France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Caen
Atopic Dermatitis
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
- Trial name
- NCT03587805
- Testing
- Tralokinumab
- Where
- 309 sites in United States, Belgium and 9 more
- Volunteers
- 1,672 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
- Trial name
- NCT05858619
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Eczema
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03089229
- Testing
- HAT01H Cream, Vehicle Cream
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Haus Bioceuticals
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
- Trial name
- NCT06891040
- Testing
- VC005 groups
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis
Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease inducing poor quality of life. Its conventional treatments often cause unsatisfactory relief and adverse effects in long-term application.
- Trial name
- NCT02844452
- Testing
- Acupuncture
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kyunghee University
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis
To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT02456480
- Testing
- CLS001, Vehicle
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Maruho Co., Ltd.
Psoriasis
Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by the formation of scaly and erythematous plaques. A Th1-cell mediated process is believed to be involved in the pathogenesis of psoriasis.
- Trial name
- NCT00372580
- Testing
- blood test
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis
Pimecrolimus and Epidermal Barrier Function
This study seeks to investigate the role of pimecrolimus in restoring disturbed skin barrier function and reversing epidermal abnormalities found in atopic dermatitis (AD).
- Trial name
- NCT01132079
- Testing
- cream treatment
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University of Kiel
Atopic Dermatitis
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children.
- Trial name
- NCT05388760
- Testing
- Tralokinumab
- Where
- 11 sites in Czechia, France and 3 more
- Volunteers
- 28 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled…
- Trial name
- NCT07054736
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Atopic Dermatitis
Jaktinib Hydrochloride Cream For Atopic Dermatitis
This study includes a dose escalation part and a dose extension part.
- Trial name
- NCT04435392
- Testing
- Jaktinib Hydrochloride Cream
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Atopic Dermatitis, Food Allergy
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for…
- Conditions
- Atopic Dermatitis, Food Allergy, Healthy
- Trial name
- NCT06300697
- Testing
- Data and biospecimen collection, Skin biopsies, Oral Food Challenge (OFC) procedures
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Dermatitis, Contact
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability…
- Trial name
- NCT00929981
- Testing
- Tablet Methylprednisolone (4 or 16 mg)
- Where
- 4 sites in India
- Volunteers
- 80 people
- Sponsor
- Pfizer
Atopic Dermatitis
Targeted Investigation of Microbiome Elimination
The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.
- Trial name
- TIME-1 (NCT05177328)
- Testing
- S. hominis A 9 Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic
Protopic Ointment in Children Atopic Eczema
Children with atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed.
- Trial name
- NCT00689832
- Testing
- Tacrolimus 0.03%, Fluticasone 0.005%
- Where
- France
- Volunteers
- 487 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.